Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2004

View Archived Issues

CTCE-0214 enters phase I studies for stem cell mobilization

RUP3 receptor as a target for diabetes and obesity

New oxytocin antagonists identified by ARS team

Novel NOS inhibitors prepared and tested at Altana

BMS claims new IKK inhibitors and their use in inflammatory and immune disorders

Chugai presents novel benzothiophene-based FTase inhibitors

Teijin scientists design novel MAPKAP-K2 inhibitors

New glucokinase activators emerge from Banyu R&D

Extension and expansion of Arena/Merck & Co. cardiovascular collaboration

New head-to-head phase III study of MedImmune CAIV-T and TIV flu vaccines

Immunomedics plans registration trials of epratuzumab in lupus

OraSure Technologies launches OraQuick Advance Rapid HIV-1/2 Antibody Test

Lundbeck files for new Alzheimer's indication for Ebixa in Europe

U.S. clinical development begins for smallpox vaccine candidate LC16m8

Positive phase II results for Corus-1020

Enrollment begins in INITIATE plus study of NovoLog Mix 70/30

Norak Biosciences and Curis sign research agreement

Orphan drug designation for 17-AAG in multiple myeloma

Nobex and Biocon to develop oral insulin product for diabetes

Formal animal toxicology study successfully completed for ACP-SL017

Avastin receives positive opinion in Europe for metastatic colorectal cancer

Gilead Sciences discontinues development of GS-9005 and GS-7340

Treatment under way in TheraSight trial

Long-term study shows Adderall XR is effective in adolescents with ADHD

Rotigotine prevents neuronal degeneration in a mouse model of PD

Therapeutic benefits of topical bimosiamose in psoriasis vulgaris

Sertraline plus sildenafil improve sexual activity of patients with premature ejaculation

New data on the pharmacokinetics and effects of topical testosterone in women

Novel antidepressant may improve side effect profile of selective serotonin reuptake inhibitors

New adenine derivative shows antidepressant-like effects in vivo

Dual opioid receptor agonist JNJ-10335572 shows good activity in in vivo GI assays

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...